Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added ...

Novo Nordisk is expanding its reach in the obesity medicines market by making its blockbuster weight loss drug Wegovy available directly to certain patients for more than half off the product’s ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...

On Tuesday, Lilly began selling higher doses of Zepbound in the U.S. at a discount of $150 compared to the injector pen versions, Reuters reported. Then, on Wednesday, it said that it would invest ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...